Defense Giants Face Post-Cold War Research Challenge

Editor's Note: Now that the Cold War is history, it's clear that the United States' mighty defense and aerospace firms increasingly will be pursuing profit in areas other than the development of military weaponry. According to the newsletter Science Watch--published by the Institute for Scientific Information (ISI) in Philadelphia--the effectiveness with which these corporations refocus their product-development attention from swords

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Many defense and aerospace firms in the United States and other nations are quickly discovering what it takes to survive in a post-Cold War world--and it's not business as usual.

As a wave of articles in financial and trade publications is telling us, many defense contractors have responded to slackening demand by selling off peripheral or weak business lines (often to their stronger competitors); by attempting to redirect their military manufacturing capabilities to civilian projects; and, generally, by downsizing.

To twist a familiar phrase, defense companies are starting to worry and learning how not to love the bomb so much. During these times of turbulent transition, each defense company will be scrutinizing its scientific and technological base to determine how best to adapt to the new environment. While aircraft and weapons manufacturers are quintessential technology shops, technology is to some degree dependent on basic research and scientific expertise. The research ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies